Pharmaceutical compositions for the treatment of Lyme disease (Borreliosis) comprising compounds capable of providing dihydroartemesinin and a pharmaceutically acceptable excipient formulated for transmucosal sublingual, buccal or nasal delivery, especially by a spray. The pharmaceutically acceptable excipient is selected from selected from medium/short chain triglycerides, omega-3-marine triglycerides and fish oil, rich in omega-3 acids. The preferred compound capable of providing dihydroartemesinin is artemether. The composition may further comprise an essential oil such as Levomenthol. Also provided are delivery devices containing the compositions.
